Piper Jaffray analyst Tyler Van Buren lowered his price target on Bluebird Bio to $85 after its Q3 earnings miss, stating that while he is eager to see its KarMMa dataset for ide-cel/bb2121 by year-end, he sees expectations of median progression free survival of 11.8 months as already relatively high. With ide-cel BLA submission having been delayed a few months from 2019-end to the first half of 2020, the analyst says it is unlikely to see any substantial revenues from the program next year. With added concerns about Bluebird Bio's launch of Zynteglo in the E.U., Van Buren is keeping his Neutral rating on the stock.